



US 20190345248A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2019/0345248 A1**
AB et al. (43) **Pub. Date: Nov. 14, 2019**(54) **FOLATE RECEPTOR 1 ANTIBODIES AND
IMMUNOCONJUGATES AND USES
THEREOF**(71) Applicant: **ImmunoGen, Inc.**, Waltham, MA (US)(72) Inventors: **Olga AB**, Millis, MA (US); **Daniel
TAVARES**, Natick, MA (US); **Lingyun
RUI**, Weston, MA (US); **Gillian
PAYNE**, Waban, MA (US); **Viktor S.
GOLDBAKHER**, Newton, MA (US)(73) Assignee: **ImmunoGen, Inc.**, Waltham, MA (US)(21) Appl. No.: **16/384,031**(22) Filed: **Apr. 15, 2019****Related U.S. Application Data**

- (62) Division of application No. 15/583,281, filed on May 1, 2017, now Pat. No. 10,301,385, which is a division of application No. 14/819,209, filed on Aug. 5, 2015, now Pat. No. 9,657,100, which is a division of application No. 13/800,835, filed on Mar. 13, 2013, now Pat. No. 9,133,275, which is a division of application No. 13/033,723, filed on Feb. 24, 2011, now Pat. No. 8,557,966.
- (60) Provisional application No. 61/307,797, filed on Feb. 24, 2010, provisional application No. 61/346,595, filed on May 20, 2010, provisional application No. 61/413,172, filed on Nov. 12, 2010.

Publication Classification(51) **Int. Cl.**

C07K 16/28 (2006.01)
A61K 31/537 (2006.01)
A61K 39/395 (2006.01)
A61K 45/06 (2006.01)
C07K 16/30 (2006.01)
A61K 47/68 (2006.01)
A61K 31/5365 (2006.01)
A61K 47/54 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/28** (2013.01); **A61K 2039/505**
(2013.01); **A61K 39/39558** (2013.01); **A61K**
45/06 (2013.01); **C07K 16/3069** (2013.01);
C07K 16/30 (2013.01); **A61K 47/6849**
(2017.08); **A61K 39/3955** (2013.01); **A61K**
31/5365 (2013.01); **A61K 47/6889** (2017.08);
A61K 47/545 (2017.08); **A61K 47/6803**
(2017.08); **A61K 47/6851** (2017.08); **C07K**
2317/73 (2013.01); **C07K 2317/526** (2013.01);
C07K 2317/53 (2013.01); **C07K 2317/71**
(2013.01); **C07K 2317/94** (2013.01); **C07K**
2317/92 (2013.01); **C07K 2317/31** (2013.01);
C07K 2317/52 (2013.01); **C07K 2317/524**
(2013.01); **A61K 31/537** (2013.01)

(57)

ABSTRACT

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

Specification includes a Sequence Listing.